Trump's Executive Order on Reducing Prescription Drug Prices Will Have Limited Impact on Indian Pharma Companies: Crisil Ratings

Trump's Executive Order on Reducing Prescription Drug Prices Will Have Limited Impact on Indian Pharma Companies: Crisil Ratings

Get latest articles and stories on Business at LatestLY. Citing the reason behind its observation, the credit rating firm in its report said that despite India exporting over half of its pharmaceutical output, the bulk comprises low-priced generic drugs, which already operate on razor-thin margins, leaving little room for further price cuts to materially affect revenues. Business News | Trump's Executive Order on Reducing Prescription Drug Price…

The Impact of 'Most Favored Nation' Policy on Clinical Development Funding

In an interview with Applied Clinical Trials, Jim Kremidas, executive director of the Association for MultiSite Research Corporations, examined the potential consequences of the Trump Administration’s ‘Most Favored Nation’ pricing policy, which aims to align US pharmaceutical prices with the lowest global rates. Drawing from his experience at Eli Lilly, Kremidas expressed concerns about the policy’s potential to reduce investment in clinical dev…

A Primer on Pharmacy Benefit Managers

President Trump signed an executive order last month to lower prescription drug costs, partly taking aim at the considerable influence of pharmacy benefit managers (PBMs). Few Americans know what PBMs are. In short, PBMs have great influence over the logistics and cashflow of the prescription drug industry, setting prices for patients and controlling their access to medicines. But what exactly do they do? Federal law first mandated prescriptions…

Indian Pharma Faces Minimal Risk From US Drug Price Cuts, Says Crisil Ratings

Crisil Ratings reported that US President Donald Trump’s executive order on prescription drug pricing will have limited impact on Indian pharmaceutical companies. The order seeks to reduce branded prescription drug prices by 30–80% through a “Most Favoured Nation” (MFN) pricing model. Crisil stated that Indian exports, which account for over 54% of the nation’s pharma output, will remain largely unaffected since they mostly include low-priced ge…